Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 7,931,387 | 7,687,853 | 8,641,388 | 7,153,412 | 8,032,829 |
| Cost of Goods | 2,476,355 | 2,509,753 | 2,195,502 | -16,337,420 | 2,430,163 |
| Gross Profit | 5,455,032 | 5,178,100 | 6,445,885 | 23,490,830 | 5,602,666 |
| Operating Expenses | 4,430,319 | 4,292,268 | 4,184,564 | 3,394,240 | 4,228,675 |
| Operating Income | 1,025,059 | 886,586 | 2,261,823 | 1,403,176 | 1,374,154 |
| Interest Expense | 411,013 | 361,052 | 646,719 | 699,426 | 601,622 |
| Other Income | 21,252 | 33,634 | 413,996 | 517,573 | 281,510 |
| Pre-tax Income | 635,298 | 559,168 | 2,029,100 | 1,221,323 | 1,054,042 |
| Income Tax | 126,482 | 140,613 | 205,278 | -621,595 | 166,637 |
| Net Income Continuous | 508,816 | 418,555 | 1,823,822 | 1,842,918 | 887,405 |
| Minority Interests | 449 | 282 | 391 | 417 | 758 |
| Net Income | $508,367 | $418,263 | $1,823,440 | $1,842,501 | $886,646 |
| EPS Basic Total Ops | 0.16 | 0.13 | 0.58 | 0.59 | 0.28 |
| EPS Basic Continuous Ops | 0.16 | 0.13 | 0.58 | 0.59 | 0.28 |
| EPS Diluted Total Ops | 0.16 | 0.13 | 0.58 | 0.58 | 0.28 |
| EPS Diluted Continuous Ops | 0.16 | 0.13 | 0.58 | 0.58 | 0.28 |
| EBITDA(a) | $2,236,071 | $2,166,473 | $3,562,650 | $21,322,380 | $2,771,860 |